Sarepta Therapeutics, Inc. (SRPT) News
Filter SRPT News Items
SRPT News Results
|Loading, please wait...|
SRPT News Highlights
- SRPT's 30 day story count now stands at 24.
- Over the past 16 days, the trend for SRPT's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
- The most mentioned tickers in articles about SRPT are GENE, DRUG and LI.
Latest SRPT News From Around the Web
Below are the latest news stories about SAREPTA THERAPEUTICS INC that investors may wish to consider to help them evaluate SRPT as an investment opportunity.
Why These 3 Nasdaq Stocks Buckled Today
The FTC's decision to sue to block a high-profile merger is weighing on biotech valuations today.
Gene-Therapy Investors Have a Powerful Ally: Patients
Imagine for a moment that you are an expert at a Food and Drug Administration advisory panel meeting trying to decide whether to vote in favor of a drug for a rare disease that robs boys of their ability to walk, eventually killing many of them by the time they reach young adulthood. During the meeting, you hear testimonials from doctors and patients, including a video showing a boy riding his bike years after receiving the therapy for the disease, known as Duchenne muscular dystrophy. At the same meeting, you also hear from FDA staff who warn you that the studies conducted by Sarepta Therapeutics don’t provide clear evidence that the drug is beneficial.
Why Is Sarepta (SRPT) Stock Up 29% Today?
Sarepta (SRPT) stock is on the move Monday as investors react to FDA advisors voting on its gene therapy for Duchenne muscular dystrophy.
Sarepta Stock Catapults Higher After Eking Out A Narrow Win In Its Gene Therapy Battle
Shares of SRPT stock launched Monday after FDA advisors voted late Friday in support of a highly anticipated gene therapy from Sarepta.
Stocks to Watch Monday: Newmont, Oneok, Shake Shack
[**Newmont (NEM)**](https://www.wsj.com/market-data/quotes/NEM): Stock in the gold miner rose 2.7% in afternoon trading after it [agreed to buy](https://www.wsj.com/articles/newmont-agrees-to-acquire-australias-newcrest-for-17-5-billion-30fe3300) Australia's Newcrest Mining, concluding weeks of talks and marking a move into copper.
Why Sarepta Therapeutics Stock Is Skyrocketing Today
Shares of Sarepta Therapeutics (NASDAQ: SRPT) were skyrocketing 24.9% higher as of 10:37 a.m. ET on Monday. The huge gain came after the company announced Friday evening that a U.S. Food and Drug Administration (FDA) advisory committee voted in support of accelerated approval of SRP-9001 in treating Duchenne muscular dystrophy (DMD). Sarepta said that the FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 8-6 in favor of approving SRP-9001.
Sarepta gains over $2B in market cap on new hope for Duchenne drug approval
The stock surge follows a key FDA committee's "yes" vote on its Duchenne drug Friday evening.
FDA AdComm Narrowly Supports Approval Of Sarepta's Gene Therapy For Rare Neuromuscular Disorder
On Friday, FDA's Cellular, Tissue and Gene Therapies Advisory Committee (CTGTAC) voted 8 to 6 in support of accelerated approval of Sarepta Therapeutics Inc's (NASDAQ: SRPT) SRP-9001 (delandistrogene moxeparvovec) for ambulatory patients with Duchenne muscular dystrophy. The FDA is slated to make a decision on accelerated approval by May 29. The agency typically follows the advice of its expert advisers but is not obligated to do so. "Today's advisory committee outcome is extremely important to
Sarepta surges after FDA panel backs Duchenne gene therapy
(Reuters) -Shares of Sarepta Therapeutics jumped 25% on Monday as a backing by the U.S. health regulator's advisers increased the certainty of an accelerated approval for the company's gene therapy for a muscle-wasting genetic disorder. Eight of the 14 advisers to the Food and Drug Administration late Friday voted that the company had enough data to support an accelerated approval for its gene therapy for Duchenne muscular dystrophy (DMD). "We are increasingly optimistic that SRP-9001 will be granted accelerated approval, especially as the panel voted in concordance with how we think senior leaders at the agency view the application," said SVB Securities analyst Joseph Schwartz.
2 Supercharged Growth Stocks to Buy Right Now
Despite a possibe economic recession, the ongoing turmoil among regional banks, rumblings of a potential crisis in commercial real estate, stubbornly high inflation, ever-rising interest rates, and a fair amount of geopolitical tumult, growth stocks have been on the upswing in 2023. The tech-heavy Nasdaq Composite, for example, has clocked a remarkable 17.4% gain so far this year. The core reason is that bargain hunters have been snapping up growth stocks of late after their dramatic decline in value in 2022.